Identification of Immune-Related Cells and Genes in Tumor Microenvironment of Clear Cell Renal Cell Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Oct 5

PMID 33014871

Citations 7

Authors

Bowen Du

Yulin Zhou

Xiaoming Yi

Tangliang Zhao

Chaopeng Tang

Tianyi Shen

Kai Zhou

Huixian Wei

Song Xu

Jie Dong

Le Qu

Haowei He

Wenquan Zhou

Affiliations

Soon will be listed here.

Abstract

Clear cell renal cell carcinoma (ccRCC) is one of the most common tumors in the urinary system. Progression in immunotherapy has provided novel options for the ccRCC treatment. However, the understanding of the ccRCC microenvironment and the potential therapeutic targets in the microenvironment is still unclear. Here, we analyzed the gene expression profile of ccRCC tumors from the Cancer Genome Atlas (TCGA) and calculated the abundance ratios of immune cells for each sample. Then, seven types of immune cells were found to be correlated to overall survival, and 3863 immune-related genes were identified by analyzing differentially expressed genes. We also found that the function of immune-related genes was mainly focused on ligand-receptor binding and signaling pathway transductions. Additionally, we identified 13 hub genes by analyzing the protein-protein interaction network, and seven of them are related to overall survival. Our study not only expands the understanding of fundamental biological features of microenvironment but also provides potential therapeutic targets.

Citing Articles

IGF2BP2 Shapes the Tumor Microenvironment by Regulating Monocyte and Macrophage Recruitment in Bladder Cancer.

Li J, Jiang Y, Ma M, Wang L, Jing M, Yang Z Cancer Med. 2024; 13(24):e70506.

PMID: 39711402 PMC: 11664238. DOI: 10.1002/cam4.70506.

Deciphering the molecular landscape: integrating single-cell transcriptomics to unravel myofibroblast dynamics and therapeutic targets in clear cell renal cell carcinomas.

Zhou W, Lin Z, Tan W Front Immunol. 2024; 15:1374931.

PMID: 38562930 PMC: 10982338. DOI: 10.3389/fimmu.2024.1374931.

Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype.

Farha M, Nallandhighal S, Vince R, Cotta B, Stangl-Kremser J, Triner D Cancers (Basel). 2023; 15(23).

PMID: 38067234 PMC: 10705373. DOI: 10.3390/cancers15235530.

The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma.

Li J, Cao J, Liang C, Deng R, Li P, Tian J Med Oncol. 2022; 39(4):41.

PMID: 35092501 DOI: 10.1007/s12032-021-01645-0.

A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases.

Li J, Cao J, Li P, Deng R, Yao Z, Ying L Int J Gen Med. 2022; 15:325-342.

PMID: 35035230 PMC: 8754506. DOI: 10.2147/IJGM.S341801.

References

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S . Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. Cancer Sci. 2019; 110(6):1820-1828. PMC: 6550131. DOI: 10.1111/cas.14019. View

Geissler K, Fornara P, Lautenschlager C, Holzhausen H, Seliger B, Riemann D . Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology. 2015; 4(1):e985082. PMC: 4368143. DOI: 10.4161/2162402X.2014.985082. View

Barata P, Rini B . Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 2017; 67(6):507-524. DOI: 10.3322/caac.21411. View

Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z . 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49(5):798-805. DOI: 10.1016/j.eururo.2005.11.035. View

Shen C, Kaelin Jr W . The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2012; 23(1):18-25. PMC: 3663044. DOI: 10.1016/j.semcancer.2012.06.001. View

Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T . Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013; 45(8):860-7. DOI: 10.1038/ng.2699. View

Hemdan N . Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. Immunol Lett. 2012; 149(1-2):123-33. DOI: 10.1016/j.imlet.2012.11.002. View

Yuan Y . Spatial Heterogeneity in the Tumor Microenvironment. Cold Spring Harb Perspect Med. 2016; 6(8). PMC: 4968167. DOI: 10.1101/cshperspect.a026583. View

10.

Li X, Bechara R, Zhao J, McGeachy M, Gaffen S . IL-17 receptor-based signaling and implications for disease. Nat Immunol. 2019; 20(12):1594-1602. PMC: 6943935. DOI: 10.1038/s41590-019-0514-y. View

11.

Giraldo N, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P . Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2017; 23(15):4416-4428. DOI: 10.1158/1078-0432.CCR-16-2848. View

12.

Gossage L, Eisen T, Maher E . VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2014; 15(1):55-64. DOI: 10.1038/nrc3844. View

13.

Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter J, Sarukhan A . Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol. 2014; 5:127. PMC: 3972476. DOI: 10.3389/fimmu.2014.00127. View

14.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

15.

Poltavets A, Vishnyakova P, Elchaninov A, Sukhikh G, Fatkhudinov T . Macrophage Modification Strategies for Efficient Cell Therapy. Cells. 2020; 9(6). PMC: 7348902. DOI: 10.3390/cells9061535. View

16.

Eckl J, Buchner A, Prinz P, Riesenberg R, Siegert S, Kammerer R . Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl). 2011; 90(1):55-66. DOI: 10.1007/s00109-011-0806-7. View

17.

Wiley S, Sriram K, Liang W, Chang S, French R, McCann T . GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J. 2017; 32(3):1170-1183. PMC: 5892729. DOI: 10.1096/fj.201700834R. View

18.

Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E . Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016; 14(10):2476-89. PMC: 4794376. DOI: 10.1016/j.celrep.2016.02.024. View

19.

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

20.

Yamaguchi T, Kifor O, Chattopadhyay N, Bai M, Brown E . Extracellular calcium (Ca2+o)-sensing receptor in a mouse monocyte-macrophage cell line (J774): potential mediator of the actions of Ca2+o on the function of J774 cells. J Bone Miner Res. 1998; 13(9):1390-7. DOI: 10.1359/jbmr.1998.13.9.1390. View